Skip to Main content Skip to Navigation
Journal articles

Drug Discovery for Kinetoplastid Diseases: Future Directions

Abstract : Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
Document type :
Journal articles
Complete list of metadatas

Cited literature [4 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-01974311
Contributor : Christel Ricard Andraos <>
Submitted on : Tuesday, January 8, 2019 - 4:53:26 PM
Last modification on : Monday, January 13, 2020 - 5:08:17 PM

Licence


Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

Identifiers

Collections

Citation

Srinivasa Rao, Michael Barrett, Glenn Dranoff, Christopher Faraday, Claudio Gimpelewicz, et al.. Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, American Chemical Society, 2018, ⟨10.1021/acsinfecdis.8b00298⟩. ⟨pasteur-01974311⟩

Share

Metrics